Deals, Alliances & News
line

Tukan Partners Ltd was established in 2005 as a business development consultancy, primarily for the biotech community.

spot

Microbiotica spins out of Wellcome Trust Sanger Institute and raises £8M in venture round with Cambridge Innovation Capital and IP Group, Cambridge, 19 Dec 2016

spot
Crescendo Biologics and Takeda Enter Collaboration for Humabody-based Therapeutics Worth up to $790m. Cambridge, Osaka, 10 October 2016

spot
Crescendo Biologics Launches New Strategy in Oncology Drug Discovery and Development. Cambridge, UK, October 2015


spot
Nature Biopharma Dealmakers: Humabodies - small and perfectly formed Cambridge, UK, May 2015

spot
Crescendo Biologics’ receives further investment from Astellas Venture Management Cambridge, UK, December 2014

spot
Chronos signs a collaboration agreement with a large pharmaceutical company for Chronoscreen technology. Oxford, UK: June 2014

spot
PsiOxus Therapeutics' MT-102 Wasting disease therapeutic shows reversal of cancer related cachexia in phase II study. Oxford, UK: 12 November2013

spot
Abcodia granted exclusive licence to Risk of Ovarian Cancer Algorithm (ROCA). London, UK: September 2013

spot
Chronos awarded $1.3M Biomedical Catalyst grant for neurodegeneration studies. Oxford, UK: August 2013

spot
Medivir has selected MIV-247 as a candidate drug for development in the treatment of neuropathic pain. Stockholm, Sweden: 10 Oct 2013

spot
Medivir reports positive results from a phase 1 study with MIV-711 for the treatment of osteoarthritis. Stockholm, Sweden: 9 Oct 2013

spot
Abcodia and BIOUNIVERSA announce collaboration on BAG3 biomarker for the early detection of pancreatic cancer. London, UK & Salerno, Italy: 23 April 2012

spot
Abcodia and VolitionRx collaboration advances discovery of blood based biomarkers for cancer. London, UK: 17 February 2012

spot
ISA Pharmaceuticals closes licence agreement with Transgene
Leiden, The Netherlands: 26 May 2011

spot
Procarta Biosystems raises £730,000 in equity financing
Norwich, UK: 12 November 2010

spot
Heptares announces $200M agreement with Novartis Option Fund
London, UK: 12 October 2009

spot
Heptares secures £21 million in Series A round
London UK: 24 February 2009

spot
Clinical Designs acquired by Mundipharma
London, UK: 2 September 2008